Novel drugs to treat acute organ inflammation
Explore Arch Biopartners platforms, teams and publications
Arch is developing new drugs, led by LSALT peptide, that are:
- designed to inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP1) pathway and,
- relevant for common organ injuries and diseases where organ inflammation is an unmet problem with no effective treatments in the market today.
About LSALT peptide
Following our scientists’ identification of DPEP1 as an adhesion receptor in the lungs, kidneys and liver and their discovery that DPEP1 was shown to be the target of LSALT peptide (Cell 2019). Arch believes that the drug has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role.
In 2024, the company is sponsoring a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). The CS-AKI trial began dosing patients in March 2024. The trial began with three active hospital sites in Turkey with a hospital site in Canada also joining in March 2024. The complete study is planned to include up to 240 patients in Turkey, Canada and the United States.
- April 2023, completed an additional Phase I trial which increased the safe dose limit of LSALT peptide.
- June 2023, obtained the U.S. FDA’s permission to proceed with the new Phase II trial to prevent cardiac surgery-associated acute kidney injury (CS-AKI).
- March 2024, dosing of first patient in Turkey marking the commencement of the Phase II CS-AKI trial, announcement of the first Canadian site to join the trial
- March 2024, publication of previous Phase II trial results providing more scientific rationale to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications
Find out more about ongoing LSALT peptide development and clinical trials.
Additional programs not currently under development:
An experienced team of scientists with an executive, board and advisors bringing deep scientific, pharmaceutical, biotechnology and corporate financial experience.
Science and Research Teams
- Current work on LSALT Peptide is directed by Arch’s Treatments for Inflammation Team, led by Dr. Daniel Muruve Ph. D., Dr. Justin Macdonald Ph. D. and Dr. Arthur Lau Ph. D, who are primarily based at the University of Calgary. David Luke, BScPhm, PharmD, is a Strategic Advisor working to support the Board of Directors and the company’s ongoing clinical trials with LSALT peptide.
- The DPEP1 Inflammation Pathway and LSALT Peptide (Metablok) were discovered by the Metablok team – Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D. and Jennifer Rahn B Sc., M Sc. at the University of Calgary.
The Arch Science team also includes:
- Dr. Randall Irvin Ph. D., Professor Emeritus at the University of Alberta whose work on the BORG Peptide is not currently under development.
And, until his passing Dr. Daniel (Dr.Dan) J. Hassett Ph.D. (May 1958-April 2022), who led the work on AB569 at the University of Cincinnati.
The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.
- Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation with broad application to prevent organ and tissue injury
- AB569 publications describing AB569 as a novel bactericidal treatment for treatment resistant bacteria and Respiratory Pseudomonas
- BORG Peptide publications discussing a peptide-based biological coating for enhanced corrosion resistance, strength and control of adhesion of bacteria and microbes.
- Brain Tumor Stem Cell Targeting publications describe the development of a peptide-based delivery platform for targeting malignant brain tumors
